ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Its product pipeline includes Ponatinib, an investigational pan BCR-ABL inhibitor, which is being studied in Phase I and II clinical trials in patients with hematologic cancers, including chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia; AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a Phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers. The company also focuses on a drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer. ARIAD Pharmaceuticals, Inc. has a collaboration agreement with Merck for the joint global development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol and ICON to develop and commercialize ridaforolimus-eluting stents and other medical devices to prevent restenosis or reblockage of injured vessels following interventions in which stents are used in conjunction with balloon angioplasty. The company was founded in 1991 and is headquartered in Cambridge, Massachusetts.